| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Asthma | D001249 | 52 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Cerebral Hemorrhage | D002543 | 13 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Polycythemia Vera | D011087 | 13 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Blood Platelet Disorders | D001791 | 12 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Renal Artery Obstruction | D012078 | 8 associated lipids |
| Atrial Fibrillation | D001281 | 16 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Death, Sudden, Cardiac | D016757 | 12 associated lipids |
| Hypoalphalipoproteinemias | D052456 | 5 associated lipids |
11-dehydro-txb2
Cross Reference
Introduction
To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 11-dehydro-txb2?
11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2
PubChem Associated disorders and diseases
What pathways are associated with 11-dehydro-txb2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What functions are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What genes are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 11-dehydro-txb2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hartanto MD et al. | Urinary 11-dehydro-thromboxane Bâ‚‚ and 2,3-dinor-6-keto-prostaglandin-Fâ‚α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. | 2012 | J. Thromb. Thrombolysis | pmid:22311294 |
| Olson MT et al. | Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. | 2012 | J. Thromb. Haemost. | pmid:23072449 |
| Ferroni P et al. | Platelet activation in type 2 diabetes mellitus. | 2004 | J. Thromb. Haemost. | pmid:15304032 |
| Ohmori T et al. | Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. | 2006 | J. Thromb. Haemost. | pmid:16706971 |
| De Cristofaro R et al. | Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. | 2003 | J. Thromb. Haemost. | pmid:12871497 |
| Li C et al. | Reversal of the anti-platelet effects of aspirin and clopidogrel. | 2012 | J. Thromb. Haemost. | pmid:22268852 |
| Lemkes BA et al. | The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. | 2012 | J. Thromb. Haemost. | pmid:22252020 |
| Santilli F et al. | Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. | 2010 | J. Thromb. Haemost. | pmid:20088941 |
| Maga P et al. | 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. | 2016 | J. Physiol. Pharmacol. | pmid:27511998 |
| Catella-Lawson F et al. | Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10215647 |